Typically, the loss of p53 isoforms β/γ expression correlates with cancer progression, whereas maintained expression correlates with an improved clinical outcome (i.e. increased survival and chemo-sensitivity, decreased tumor size and recurrence etc.)9,11,16. Here, TP53 is linked to cancer.